UpdatesPlus Nicotinic Receptors - Current Research and Development - July 2009
Is your company active in the field of nicotinic therapeutics? Subscribe to UpdatesPlus now and keep up to date with events in this field and find out how your pipeline may be affected
Neuronal nicotinic receptor ligands are fast proceeding through clinical development as exciting candidates for multiple CNS disorders including Alzheimer's disease; Schizophrenia; ADHD; Depression; Pain and Addiction.
More recently we have been seeing the field expand with peripheral nicotinic receptors gaining increasing attention in relation to further indications including various inflammatory conditions
Are you involved in these areas; are you developing a nicotinic receptor ligand? If so UpdatesPlus is for you. This service, brought to you from the pharmaceutical analysts, LeadDiscovery, not only identifies all key breaking research, drug development news and clinical trials in this area, it also analyzes it.
Published monthly along with fully up to date pipelines, UpdatesPlus offers a key insight into strategy and development as well as new research advances. Offering an ideal intelligence tool for everyone from brand managers to medical directors and preclinical managers, UpdatesPlus is a must for all involved in this exciting new field of medicine. Well over half the companies involved in nicotinic receptors subscribe to UpdatesPlus. To see what you are missing open the free issue below
See February 2008 edition now (free sample copy)
Table of Contents
What's in the June 2009 edition of UpdatesPlus-Nicotinic Receptors?
α7 nicotinic receptors
- EnVivo Pharmaceutical - A company with increasing stature in the nicotinics arena
- Does Pfizer currently have an alpha7 agonist in clinical development? Pfizer started clinical development of two nootropic candidates in Q4 2008. We believe that at least one of these candidates is an alpha7 agonists which may soon enter Phase 2 development
- Threats to the nicotinic class - Most candidate treatments of cognitive impairment associated with schizophrenia are from the nicotinic class. Recent data sees Allon's Davunetide threatening this class however we believe that the nicotinics remain the most promising class
- Full and up to date α7 receptor pipeline
α4ß2 nicotinic receptors
- Targacept's dream month - AZD3480 comes back from the dead while new data on TC-5214 suggests blockbuster potential
- The unfolding story of alpha4beta2 agonists as treatments of Alzheimer's disease - what has happened to ABT-089? Is this indication dead for alpha4beta2 agonists? We think not but improved screening models are required to predict nootropic efficacy and select dose; such a model may have arrived
- Full and up to date α4β2 receptor pipeline
Smoking cessation - Nicotine addiction
- Chantix's new boxed warning - What is the impact of this for Pfizer as well as manufacturers of other smoking cessation products including Zyban, nicotine replacement therapies and reduced harm smokeless tobacco products?
- Full and up to date pipeline of smoking cessation therapeutics
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
2008 issues:
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September
- October
- November
- December
2009 issues:
- January 2009
- February 2009
- March 2009
- April 2009
- May 2009
- June 2009
Table of Contents
Other users found this report page using the following search terms: Neuronal Nicotinic Receptors MEM 63908 R4996 ABT-107 TC-5619 EVP-6124 AZD-0328 SSR-180711 gts-21 MEM 3454 R3487 TC-6499 abt-560 AZD3480 TC-1734 tc-5214 ispronicline abt-894 ABT-089 nicotinic receptors cognition cognitive cias amyloid depression smoking cessation alpha7 alpha6 alpha4beta2 adhd memory nicotinic receptors varenicline champix chantix wellbutrin nicotinic receptor neuronal receptors abt894 schizophrenia ssr180711 nicotine nicotinic receptors alzheimers abt nicvax nic002 quitpak Niccine evt 302 Niquitin Targacept gsk abbott cytos nabi novartis Celtic Pharma pfizer evotec NeuroSearch servier siena wyeth roche LeadDiscovery Pharmaceutical reports Market Research market research reports pharmaceutical business reports Pharmaceutical Market Research Reports reports pharmaceutical research pipeline LeadDiscovery Pharmaceutical reports Market Research market research reports pharmaceutical business reports Pharmaceutical Market Research Reports reports pharmaceutical research pipeline nicotinic 2009 pfizer receptor davunetide pipeline receptors nicotinics monthly july
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.